Expanded cord blood stem cells and engineered human endothelial cells(Angiocrine)

N/A

Report date: 2022/12/30 14:34:13

Base Information

Drug NameExpanded cord blood stem cells and engineered human endothelial cells(Angiocrine)
Drug Alias NameExpanded cord blood stem cells and engineered human endothelial cells(Angiocrine)AB-110
ClassificationCell and gene therapy > Cell therapy > Stem cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAngiocrine Bioscience Inc
China Registration ClassN/A

Develop Information

Active CompaniesAngiocrine Bioscience Inc
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A